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AbstrACt
Introduction Chemotherapy is the mainstay of treatment 
for patients with advanced soft tissue sarcomas (STS). 
Treatment intent is usually palliative, aiming to improve 
symptoms, stabilise or reduce tumour burden and extend 
life. Clinical trials have traditionally used radiological 
response, time to progression and survival as measures of 
treatment efficacy. Health- related quality of life (HRQoL) is 
at least equally important or more important than survival 
for many patients with advanced cancer. Systematically 
collecting HRQoL data during chemotherapy can provide 
greater insight into treatment efficacy from the patient 
perspective.
The primary aims of this study are to evaluate HRQoL in 
patients with advanced STS treated with chemotherapy 
over time, explore the decision- making process and 
patient reflection post- treatment.
Methods and analysis This is an observational, 
international cohort study for 132 patients aged ≥18 
years with advanced STS treated at eight centres 
(three in the UK, five in the Netherlands). Patients will 
be recruited prior to starting first- line or third- line 
chemotherapy and invited to complete questionnaires 
using the Patient- Reported Outcomes Following Initial 
treatment and Long- term Evaluation of Survivorship 
registry (PROFILES); an established international registry 
for collection of cancer patient- reported outcomes. 
Online (or paper) questionnaires will be completed at 
baseline, each cycle of chemotherapy and 2–3 monthly 
during follow- up. The questionnaire package includes 
the Decisional Conflict Scale, Control Preferences Scale, 
Quality–Quantity Questionnaire, treatment expectations, 
European Organisation for the Research and Treatment 
of Cancer Quality of Life Questionnaire Core 30 (EORTC- 
QLQ- C30), EORTC financial toxicity items, Work Ability 
Index, Functional Assessment of Cancer Therapy- General 
(FACT- G) items and Decisional Regret Scale. Clinical data 
will be extracted from patient records and linked with 
questionnaire responses. The primary outcome measure 
is the change in global HRQoL from baseline to after cycle 
4 of first- line chemotherapy (based on published data 
showing that patients with advanced STS complete a 
median number of four cycles of first- line chemotherapy).
Ethics and dissemination Heath Research Authority 
and Research Ethics Committee (REC 17/NI/0197). 
Results from the Health- related quality Of Life In patients 
with advanced Soft TIssue sarcomas treated with 
Chemotherapy (HOLISTIC) study will be published in peer- 
reviewed journals and disseminated at local, national and 
international conferences. We will also present our findings 
at any appropriate patient meetings and involve patients in 
study- related publications.
trial registration number NCT03621332.
bACkground
Soft tissue sarcomas (STS) are a group of rare 
and heterogeneous tumours, which account 
for approximately 1% of solid malignan-
cies in adults.1 Due to the rarity and diverse 
presentation of STS, diagnosis can be delayed 
and around 10% of patients will be present 
with metastatic disease.2–5 Furthermore, 
many STS demonstrate an aggressive pheno-
type and approximately half of patients with 
intermediategrade or high grade localised 
tumours will develop metastatic disease after 
initial curative treatment.3 6 Despite advances 
strengths and limitations of this study
 ► Questionnaire data will be collected using the on-
line Patient- Reported Outcomes Following Initial 
treatment and Long- term Evaluation of Survivorship 
system (PROFILES); a well- established electronic 
platform for the collection of patient- reported out-
comes such as health- related quality of life (HRQoL).
 ► The longitudinal design of the study enables analy-
sis of HRQoL across treatment lines.
 ► Although a validated HRQoL questionnaire specifi-
cally for patients with soft tissue sarcoma has not 
yet been developed, the study questionnaire pack-
age was developed in collaboration with patients 
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in the treatment of many other cancers, the prognosis 
for patients with advanced, inoperable STS remains poor 
with a median overall survival of 12–19 months.7 8
Chemotherapy is the mainstay of treatment for patients 
with advanced STS. Other options include active surveil-
lance for those with indolent or asymptomatic disease, 
radiotherapy or local therapies (eg, radiofrequency abla-
tion or surgery) for patients with oligometastases, and 
best supportive care for those with end- stage disease 
and poor performance status (PS).6 The principal aims 
of chemotherapy are to ameliorate symptoms, slow or 
halt tumour growth and prolong survival.9 Standard 
first- line treatment, for the majority of STS subtypes, is 
anthracycline- based chemotherapy (usually doxoru-
bicin), administered 3 weekly up to a maximum of six 
cycles due to the risk of cumulative cardiotoxicity. The 
combination of doxorubicin with ifosfamide is associated 
with higher response rates and longer progression- free 
survival, however with no improvement in overall survival 
and at the expense of increased toxicity.10 Doublet 
therapy may be considered for certain patients in whom 
a rapid response is clinically desirable, such as those with 
highly symptomatic chemosensitive disease.10 Other first- 
line chemotherapy regimens include weekly paclitaxel 
for patients with angiosarcoma and (rarely) low dose 
cyclophosphamide±prednisolone for frail, often elderly 
patients.11 12 A number of systemic agents are available 
following first- line anthracycline- based therapy, including 
trabectedin, pazopanib, gemcitabine±docetaxel, dacarba-
zine and eribulin.
Radiological response to first- line chemotherapy for 
advanced STS ranges from 10% to 50% (according to 
response evaluation criteria in solid tumours (RECIST 
V.1.1)), and is dependent on patient- specific- factors 
(eg, PS), tumour histology and chemotherapy regimen.6 
Treatment decisions are often challenging due to 
modest response rates and potential treatment- related 
adverse side effects. For many patients with advanced 
cancer, health- related quality of life (HRQoL) is equally 
important or more important than survival when making 
treatment decisions.13 14 HRQoL is a multidimensional 
concept that represents the patient’s perception of a 
disease and its treatment on physical, psychological and 
social aspects of their life.15 Systematically collecting 
HRQoL data over time may provide greater insight into 
treatment efficacy from the patient perspective and may 
enable a more detailed assessment of the risk–benefit 
ratio of chemotherapy for each individual patient.16
The efficacy of systemic therapies in patients with 
cancer has traditionally been evaluated with dimensional 
radiological response, progression- free survival and 
overall survival. The burden of symptoms in patients with 
advanced STS is high, particularly pain and dyspnoea.17 
Despite the high symptom burden and palliative intent of 
treatment for most patients with advanced STS, the degree 
to which chemotherapy reduces symptoms of disease, 
improves or stabilises daily functioning and impacts 
HRQoL has rarely been measured or incorporated in 
the main endpoints of clinical trials.15 Collecting patient- 
reported outcomes (PROs), such as HRQoL, is increas-
ingly recognised to be key to fostering patient- centred 
care and influencing clinical decision- making.18 Patients’ 
perspectives can also influence treatment decisions in 
an era of rising treatment costs and limited resources. 
Collection of PROs during chemotherapy has been well 
described.19 20 Patient self- reporting improves symptom 
detection as clinicians frequently underestimate toxicities 
associated with systemic chemotherapy.20 21 Recording 
electronic PROs in real time can also improve HRQoL, 
patient–provider communication, reduce hospitalisation 
and improve survival.22
Existing research into the HRQoL of patients with 
sarcoma has primarily focused on survivors of localised 
extremity STS, or specific subgroups of patients with 
advanced STS.23–26 For example, the SABINE study eval-
uated HRQoL among patients with metastatic STS or 
bone sarcoma who had attained a favourable response 
to chemotherapy.27 The PALETTE trial of pazopanib 
versus placebo, as second- line treatment (or greater) 
for patients with advanced STS, evaluated HRQoL as 
an exploratory endpoint.28 Although pazopanib did 
not improve HRQoL, meaningful improvement in 
progression- free survival was demonstrated with no asso-
ciated impairment of HRQoL28 Hugdens et al analysed 
HRQoL for patients with advanced STS treated within the 
phase 3 trial of eribulin versus dacarbazine.29 This anal-
ysis demonstrated lower global health status and physical 
functioning scores, significantly worse loss of appetite, 
nausea and vomiting and insomnia in patients treated 
with dacarbazine on progression compared with patients 
treated with eribulin.29 The REGOSARC study of meta-
static STS patients refractory to doxorubicin, posthoc 
quality- adjusted survival benefit analysis demonstrated 
superiority of regorafenib over placebo.30 The SARC021 
phase 3 trial of doxorubicin versus doxorubicin plus 
evofosfamide reported no difference in HRQoL between 
treatment arms, despite a higher incidence of adverse 
events in the combination treatment arm.8 The phase 3 
randomised study of trabectedin versus dacarbazine in 
patients with metastatic leiomyosarcoma or liposarcoma 
after failure of conventional chemotherapy used patient- 
reported symptom scoring.31 A variety of HRQoL instru-
ments were used to collect data in these studies as no 
specific HRQoL tool exists for STS—primarily due to the 
heterogeneity of this group of patients.16 26
In order for patients with advanced STS to make a well- 
informed decision about chemotherapy and consider 
the possible effects on all aspects of their lives, clinicians 
should be able to provide HRQoL data. This will enhance 
the shared decision- making process between clinicians 
and their patients. To the best of our knowledge, this is 
the first study for patients with advanced STS which will 
evaluate HRQoL across chemotherapy treatment lines, 
consider the decision- making process (expectations and 
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MEthods/dEsIgn
The Health- related quality Of Life In patients with 
advanced Soft TIssue sarcomas treated with Chemo-
therapy (HOLISTIC) study is a longitudinal cohort 
questionnaire study for patients with advanced STS 
treated at eight sarcoma centres: three in the UK and 
five in the Netherlands (NL). The principal aim of this 
study is to assess how first- line chemotherapy affects 
global HRQoL over time (specified below) in patients 
with advanced STS. This study also aims to assess patient 
functioning (physical, psychological, emotional, social 
and role) and symptoms, before, during and after treat-
ment with chemotherapy. The study will also explore 
treatment decision- making (expectations and prefer-
ences), financial toxicity of treatment and decisional 
regret after treatment. Detailed outcome measures are 
defined below.
Patient and public involvement
The study concept was developed in consultation with 
patient advocates, patients and their relatives, who felt 
that there was a lack of information on HRQoL in patients 
receiving chemotherapy for advanced soft tissue sarcoma 
in order to make a well- informed decision about treat-
ment. Study documents were reviewed by the patients 
who are members of the Royal Marsden Hospital Patient 
and Public involvement panel. The panel provided feed-
back on the protocol, questionnaires, patient information 
sheet and informed consent form, with regard to content 
and readability. All suggestions were considered and 
changes incorporated in the final documents. In order 
to reduce time burden for patients, the questionnaire 
package was designed to minimise questionnaire fatigue. 
Patients will be involved in study- related presentations 
and publications.
Eligibility criteria and materials
Inclusion criteria
Eligible patients must be aged ≥18 years with a diagnosis 
of advanced (not amenable to curative surgical resection) 
or metastatic STS, as confirmed by a sarcoma histopathol-
ogist, and has decided to start palliative chemotherapy 
following consultation with their oncologist. Patients 
must be enrolled prior starting first- line chemotherapy or 
third- line chemotherapy. Patients must be able to commu-
nicate in English or Dutch, and have mental capacity to 
provide informed consent and participate in the study (as 
determined by their treating physician). Patients must be 
able to complete questionnaires themselves, which is a 
prerequisite for patient- reported outcomes. Participants 
must be treated at one of the participating centres.
Exclusion criteria
Due to significantly different treatment protocols, patients 
with Ewing sarcoma, rhabdomyosarcoma, desmoplastic 
small round cell tumour and gastrointestinal stromal 
tumour are not eligible for the study.
Data collection
Data collection and online questionnaire administration 
will be done within the ‘PROFILES’ registry (Patient- 
Reported Outcomes Following Initial treatment and Long 
term Evaluation of Survivorship; www. profilesregistry. nl). 
The ‘PROFILES’ registry was established in the Nether-
lands (2009) for the study of the physical and psychoso-
cial impact of cancer and its treatment in short- term and 
long- term cancer survivors.32 Since PROFILES has been 
established, studies have recruited over 30 000 patients, 
resulting in more than 100 scientific publications. Secu-
rity of the PROFILES server is established in accordance 
with current European norms (NEN- ISO/IEC 27002). 
Questionnaire data which are collected from participants 
(UK and NL) through the PROFILES registry is stored 
on a secure server in the Netherlands. This application 
has been developed to the requirements of the higher 
education and research community using end- to- end 
encryption.
recruitment
Patients will be identified by a member of the sarcoma 
team who will check eligibility criteria using electronic 
patient records. Patients will be invited to participate in 
the outpatient clinic, provided with a patient information 
sheet and given the opportunity to ask any questions to 
a member of research team. Interested patients will be 
given the option to participate online or using paper 
versions of the questionnaire. Those who prefer online 
participation will receive an email which includes a link to 
the secure PROFILES website, unique username and pass-
word. The US Food and Drug Administration have made 
it clear that electronic capture of clinical trial source data 
is preferred over paper- based data collection.33 There 
is now widespread use of electronic patient reported 
outcome measures (PROMs) within clinical trials, and 
several reviews and meta- analyses have shown evidence of 
equivalence between electronic and paper administration 
of PROMs.34 35 In order to ensure that patients are not 
excluded if they are unable to use a computer, we have 
provided the option for paper questionnaire completion. 
Paper copies of the questionnaires will be entered using 
the data entry option of PROFILES, after which a quality 
control check will take place. This online data entry portal 
minimises the chance of errors as the answer options are 
selected from electronic lists. This also ensures that the 
paper questionnaire data can be extracted in the same 
format as the online questionnaire data. The PROFILES 
data manager will randomly choose five participants who 
have completed paper questionnaires and check the data 
entry for complete accuracy. If any errors are found, then 
all data will be rechecked and corrected where necessary.
All participants will complete an informed consent 
form. This can be done electronically (using PROFILES 
personal login details) or on paper if the patient prefers a 
hard copy. Patients are assured that non- participation has 
no consequences for their treatment or follow- up care.
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After informed consent, patients will be invited to 
complete the online (or paper) baseline questionnaire. 
This must be completed before starting first- line chemo-
therapy or third- line chemotherapy (third- line patient 
cohort). Patients can complete the online question-
naire on their own computer, tablet or mobile phone, or 
using a hospital computer if available. Patients who have 
completed the baseline questionnaire will then receive an 
email on day 1 of each cycle of chemotherapy, inviting 
them to complete a new questionnaire using their existing 
login details (usually every 3 weeks). Patients who prefer 
paper versions will be handed a hard copy of the ques-
tionnaire in the chemotherapy clinic, with the option to 
return this by mail using the prepaid envelopes provided, 
or hand to the research team in a sealed envelope. If 
chemotherapy is delayed for any reason, patients will be 
invited to complete the questionnaire when treatment 
has restarted. Baseline questionnaires will take around 
20 minutes to complete and subsequent questionnaires 
will take around 10–15 minutes. Patients will complete a 
maximum of eight questionnaires during chemotherapy 
to reduce the potential for questionnaire fatigue. Patients 
have a 2- week period to complete each questionnaire and 
will be sent an electronic or paper reminder after 1 week 
if they have not completed a questionnaire.
When a participant stops first- line chemotherapy, or 
third- line chemotherapy (respective cohorts), for any 
reason (eg, all cycles completed, or disease progres-
sion), he/she will be invited to complete an ‘end of 
chemotherapy’ questionnaire. Patients will receive this 
invitation approximately 3 weeks after the last dose of 
chemotherapy. Thereafter, patients who have received 
first- line chemotherapy will be invited to complete 
3 monthly follow- up questionnaires, and patients in the 
third- line chemotherapy cohort will complete 2 monthly 
follow- up questionnaires (due to the shorter prognosis). 
If a participant starts a new line of chemotherapy (eg, 
second- line chemotherapy) during the follow- up period, 
he/she will remain on the same follow- up schedule of 
questionnaires in order to follow the trajectory of their 
HRQoL during second- line treatment and beyond. Due 
to concern about questionnaire fatigue, it was felt that 
patients who had already completed 3- weekly question-
naires during first- line chemotherapy should remain on 
the 3 monthly follow- up schedule, rather than receiving 
questionnaires at the beginning of each cycle of second- 
line chemotherapy. Due to the time frame of the study, 
we will simultaneously recruit patients beginning third- 
line treatment to explore HRQoL in patients with 
advanced STS who are further along their treatment 
trajectory.
Participants will be invited to complete follow- up ques-
tionnaires until he/she chooses to stop, is too unwell to 
continue or death occurs, whichever comes first, and up 
to a maximum of 2 years after study enrolment. Partici-
pants will only be enrolled once; either prior to first- 
line chemotherapy or before third- line chemotherapy. 
Throughout the study, it is the responsibility of the local 
sarcoma team to inform the study coordinator if a partic-
ipant has died or is too unwell to continue.
Case report forms
After a patient has provided informed consent, clinical 
data will be collected from electronic patient records 
by a member of the research team. Data collection and 
storage will be maintained according to ICH- GCP (inter-
national good clinical practice) standards. Clinical details 
will be entered into the password protected database 
(MACRO) and stored using an anonymous patient iden-
tifier number. Personal identifiable clinical data of the 
patient will not leave the hospital where the patient is 
treated.
Case report forms (CRF) will be completed at four 
timepoints during the study. The first CRF should be 
completed after patient consent, and includes docu-
mentation of eligibility criteria, date of diagnosis of 
sarcoma, histological subtype and chemotherapy treat-
ment regimen. The second part of the CRF should be 
completed when a patient stops first- line chemotherapy 
(or third- line chemotherapy for the third- line cohort). 
Information gathered at this timepoint includes reason 
for discontinuation of chemotherapy (eg, disease progres-
sion). The third point for CRF completion occurs when a 
patient stops participation in the study (eg, patient pref-
erence) and includes details of all chemotherapy regi-
mens received during the study. The final point for CRF 
data collection is death notification, where applicable.
At the end of the study, questionnaire data will be linked 
with the clinical data contained within the CRF database 
using patient study numbers. Data linkage will be done 
by the study statistician at the Royal Marsden Hospital. 
Data will be recorded and retained in accordance with 
the Data Protection Act 1998.
Questionnaires
The baseline questionnaire contains questions on socio-
demographic characteristics of the participant, such 
as marital and occupational status. Patients will also be 
asked a single screening question on health literacy which 
has validated among cancer patients and used in previous 
Dutch studies.36 37
The following internationally validated question-
naires and published questionnaires in studies of cancer 
patients will be used. These questionnaires have not 
been specifically validated in patients with advanced 
STS, however no STS- specific questionnaire has been 
developed to date. Permission to use all questionnaires 
has been obtained from authors. Formal licences are not 
required. Patients were involved in the design and review 
of the questionnaire package. All questionnaires were 
available in English. The Dutch questionnaire package 
was developed using validated Dutch versions of the 
questionnaires where possible or existing online Dutch 
translations of the questions. Where existing translations 
were not available, bilingual speakers assisted with formal 
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foward–backward translation of questions and discrepan-
cies resolved by OH (details below).
EortC-Quality of Life Questionnaire (EortC-QLQ-C30)
The European Organisation for the Research and Treat-
ment of Cancer Quality of Life Questionnaire Core 30 
(EORTC- QLQ- C30) V.3.0 was developed to assess QoL in 
patients with cancer. It has been translated and validated 
in over 100 languages, including English and Dutch. This 
questionnaire has 30 items, consisting of five functional 
scales (physical, role, cognitive, emotional and social), a 
global quality of life scale, three symptom scales (fatigue, 
pain, nausea and vomiting) and single items assessing 
common symptoms (dyspnoea, loss of appetite, sleep 
disturbance, constipation and diarrhoea) and perceived 
financial impact of the disease.38 After linear transfor-
mation, all scales and single- item measures range in 
score from 0 to 100. A higher score on functional scales 
and global QoL means better functioning and HRQoL, 
whereas a higher score on the symptom scales means 
more complaints.38
Financial toxicity
Financial toxicity questions were selected from the item 
bank of the EORTC computer adaptive testing instru-
ment and are validated in both English and Dutch 
languages.39 In combination with the EORTC- QLQ- C30 
questionnaire, these questions will maximise information 
surrounding the financial impact of advanced STS and its 
treatment. This is particularly relevant for patients with 
rare cancers, such as STS, who may need to travel long 
distances to receive care at a specialist centre.40
Functional Assessment of Cancer Therapy-General
The Functional Assessment of Cancer Therapy- General 
(FACT- G) is a validated questionnaire which has been 
widely used to measure HRQoL in patients with cancer. 
The FACT- G has been translated and validated in many 
languages including English and Dutch.41 42 Patients are 
asked to rate their response to several statements on a 
5- point Likert scale from ‘not at all’ to ‘very much’.41 We 
have selected two items from the FACT- G questionnaire:‘I 
am bothered by side effects of treatment’ and ‘I am able 
to enjoy life’ as a summary measure of the burden of a 
given set of toxicities.43 Single items from the FACT- G 
questionnaire are not validated, however 'bother' from 
side effects has been shown to be associated with patients’ 
ability to enjoy their lives.43
Control Preferences Scale
This validated questionnaire is designed to measure 
patients’ preferred role in decision making versus their 
doctor’s role.44 Patients are asked to choose from five 
options the phrase that best describes the role that 
they have taken in dealing with their cancer diagnosis 
and treatment decisions, and the role that they would 
have preferred (active/collaborative/passive role).44 
Understanding patient preferences for control in treat-
ment decision- making is crucial to improving shared 
decision- making and providing patient- centred care.45 46 
Dutch translations of the Control Preferences Scale are 
available and have been used in previous studies in the 
PROFILES registry.47
Decisional Conflict Scale
The Decisional Conflict Scale measures personal percep-
tion of decision- making, and certainty or uncertainty 
over their choice.48 This includes determining the level 
of information and support to make the choice, whether 
the decision was in line with patient values and how satis-
fied they are/were with their decision. Items are given a 
score value of 0 (no) or 1 (yes). The total score can only 
be calculated if all four items are answered. The sum of 
the four items will range from 0 (extremely high deci-
sional conflict) to 4 (no decisional conflict). A score of 
≤3 indicates decisional conflict.48 This four- item version 
of the Decisional Conflict Scale Questionnaire ('SURE') 
has been validated in English and a Dutch translation 
is available (psychometric properties have been partly 
confirmed in Dutch patients).49
Quality–Quantity Questionnaire
The Quality–Quantity Questionnaire (QQQ) tool is a 
validated construct consisting of eight questions which 
measure patient attitudes towards the trade- off of between 
quantity of life versus QoL (four questions for length of 
life (LOL) and four questions for QOL).50 A separate 
score is calculated for LOL and QOL. The total score 
for all four questions (LOL or QOL) is calculated and 
the minimum score (4) is then subtracted. This answer 
is then divided by the range (20-4) to create a rescaling 
of 0–100. For example, if a person scores 3 (midpoint 
answer) for all four questions, the calculation would be: 
(12-4)/(20-4)=0.50 (midpoint overall score).50 Decision- 
making in patients with advanced STS is extremely 
complex. Patient preferences for LOL and QOL are of 
utmost importance when weighing up the benefits and 
risks of treatments such as chemotherapy. Responses to 
these questions will allow insight into the preferences of 
patients with advanced STS and may help to inform shared 
treatment decisions.The original QQQ was written in the 
Dutch language (Professor Stiggelbout from the Nether-
lands) and has been translated and validated in English.50
Expectations of treatment
After the decision has been made to receive chemo-
therapy, patients are asked how likely they think that 
chemotherapy will improve survival, cure their cancer 
and improve symptoms due to cancer.51 Studies in 
patients with other metastatic solid tumours have shown 
that patients often overestimate their life expectancy and 
many believe that chemotherapy will be curative.51 Prog-
nostic awareness has been associated with worse HRQoL 
in patients newly diagnosed with incurable (lung or GI) 
cancer.52 This question will be used to assess expectations 
of chemotherapy among advanced STS patients. These 
questions were originally written in English and therefore 
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bilingual speakers performed a forward–backward trans-
lation of the questions into Dutch under the supervision 
of OH.
Work Ability Index
The Work Ability Index (WAI) consists of questions which 
assess the ability to work, taking into account the demands 
of the work, health status and resources.53 There are 
seven questions from which we selected two general ques-
tions to inform future patients who are receiving chemo-
therapy on their potential ability to work during and after 
chemotherapy. These two questions are scored 0–10 and 
1–6, respectively, and will be described in the analysis.53 
The WAI was developed in Finland and is available in 24 
languages, including English and Dutch.54 The validity 
and reliability of the WAI has been assessed in correlation 
analyses and used in many international research studies.
Decisional Regret Scale
Patients are asked to think about the decision they have 
made to receive chemotherapy and answer five state-
ments on how strongly they agree/disagree: (1) it was the 
right decision, (2) I regret the choice that I made, (3) I 
would go for the same choice if I had to do it over again, 
(4) the choice did me a lot of harm and (5) the decision 
was a wise one.55 Items 2 and 4 should be reverse- coded 
so that, for each item, a higher number will indicate more 
regret. To help others interpret the score more readily 
with other scales ranging from 0 to 100, these scores 
can then be converted to a 0–100 scale by subtracting 1 
from each item then multiply by 25.55 To obtain a final 
score, the items are summed and averaged. A score of 0 
means no regret; a score of 100 means high regret.55 The 
Decisional Regret Scale can be used to measure distress 
or regret after a healthcare decision such as the choice 
to receive chemotherapy. Regret about the decision to 
receive chemotherapy has not been previously measured 
in patients with advanced STS. The Decision Regret Scale 
is available in English and Dutch; Dutch translation by 
Leiden University Medical Center under supervision 
of Professor Dr Stiggelbout and Dr Pieterse, November 
2010.56
timepoints
Questionnaire A is the baseline questionnaire, which 
should be completed before starting chemotherapy.
Patients are invited to complete Questionnaire B on 
day 1 of cycle 1 of first- line chemotherapy or third- line 
chemotherapy (third- line cohort). Patients are invited to 
complete Questionnaire C on day 1 of every cycle from 
Cycle 2 onwards and 3 weeks after the last cycle of chemo-
therapy. Questionnaire D is the follow- up questionnaire 
which is completed every 3 months after the end of 
chemotherapy for first- line chemotherapy patients, and 
every 2 months for the third- line chemotherapy patient 
cohort. Patients have a 2- week window to complete each 
questionnaire and will be sent a reminder after 1 week 
if they have not completed the questionnaire. Table 1 
summarises enrolment, timepoints, the questions which 
are included in each questionnaire and the number of 
questions in each questionnaire.
Endpoints
The primary endpoint is change in EORTC- QLQ- C30 
global HRQoL score (continuous scale) after treatment 
with first- line chemotherapy. Secondary endpoints are 
change in EORTC- QLQ- C30 physical, cognitive, social, 
role and emotional functioning scores (continuous) after 
treatment with first- line chemotherapy, and change in 
EORTC- QLQ- C30 symptoms (continuous) after treat-
ment with first- line chemotherapy.
The study will also explore change in EORTC- QLQ- C30 
global HRQoL score, EORTC- QLQ- C30 functioning 
scales and symptom scores after treatment with third- line 
chemotherapy (third- line patient cohort).
For all patients, we will examine whether there is 
an association between sociodemographic and clin-
ical factors (including age, gender, relationship status, 
educational level, PS, tumour subtype, site of metastases, 
baseline anaemia (Hb <13 g/L male, <11.5 g/L female), 
lymphopoenia <1×109/L, lactate dehydrogenase (LDH) 
>250 U/L, hypoalbuminaemia <35 g/L) and baseline 
EORTC- QLQ- C30 global HRQoL and/or change in 
physical, cognitive, social, role and emotional func-
tioning during and after treatment. The study will eval-
uate whether there is an association between HRQoL 
and radiological response (according to RECIST V.1.1) 
to chemotherapy, and between HRQoL and financial 
toxicity.
The study will explore work ability in patients with 
advanced STS treated with chemotherapy, patient pref-
erences for collaborative decision- making, decisional 
conflict about treatment, expectations of treatment with 
chemotherapy, preferences for quantity of life versus 
QoL and retrospective views on their decision to receive 
chemotherapy.
statistical analysis and power calculation
Primary endpoint
Change in EORTC- QLQ- C30 global HRQoL score will be 
tested using a paired sample t- test from baseline to after 
four cycles with a two- sided 5% significance level. For 
patients who do not complete four cycles, the last score/
observation (post baseline) will be carried forward for the 
analysis. Four cycles was chosen as the timepoint for the 
analysis based on a study of 488 patients with advanced 
STS treated at the Royal Marsden Hospital, showing that 
patients completed a median number of four cycles of 
chemotherapy (range 1–8).57
A sensitivity analysis will also be performed excluding 
those patients who do not reach four cycles.
If data are not normally distributed, then the Wilcoxon 
test will be used.
Secondary endpoints
Differences in physical, cognitive, social, role, emotional 
functioning and symptoms from baseline measurements 
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 Questionnaire A Questionnaire B Questionnaire C Questionnaire 
D
Sociodemographic questions (15)  X
Health literacy (1)  X
Control Preferences Scale (2)  X
Decisional Conflict Scale (4)  X
Quality Quantity Questionnaire (8)  X X X
Expectations of treatment (3)  X X X –
EORTC- QLQ- C30 (30)  X X X X
Work Ability Index (3)  X X X X
EORTC CAT items: financial 
difficulties (5)
 X X X X
FACT- G items (2)  – X* X X
Decisional Regret Scale (5)  – – X X
Total number of questions  71 50 56 45
*FACT- G, cycle 1 questionnaire includes the single statement ‘I am able to enjoy life’. Cycles 2–8 and follow- up questionnaires include the 
additional statement ‘I am bothered by the side effects of treatment’.
EORTC CAT, European Organisation for the Research and Treatment of Cancer computer adaptive testing; EORTC- QLQ- C30, European 
Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30; FACT- G, Functional Assessment of Cancer 
Therapy- General.
over time will be analysed using mixed models, to allow 
for the repeated nature of the data by including subject as 
a repeated effect, and associations across visits (included 
as a fixed) will be investigated. The baseline score will also 
be fitted as a fixed effect in all models.
Exploratory endpoints
HRQoL of patients treated with third- line chemotherapy 
over time will be presented descriptively at each timepoint.
The association between sociodemographic and clinical 
factors (including age, gender, relationship status, educa-
tional level, PS, tumour subtype, site of metastases and 
baseline laboratory values), financial toxicity and radio-
logical response with global HRQoL, physical, cognitive, 
social, role, emotional functioning and symptoms at each 
timepoint will be analysed using univariate mixed models 
as above. First time- invariant variables (eg, sex, race and 
age at diagnosis) will be assessed and then time- variant 
variables to evaluate whether time- specific conditions 
influence a linear trend of HRQoL over time. Interac-
tions between factors and time will also be explored to 
assess whether trajectories of HRQoL over time differed 
by subgroups.
A multivariate model will be constructed as a function 
of time, sociodemographic and clinical characteristics, 
and interactions between time and other covariates. Any 
factors found significant (p<0.05) in univariate analysis 
will be tested in a multivariate mixed- effects models to see 
if factors of QOL are independent of each other. A back-
ward selection method will be used (p<0.05) to identify a 
parsimonious model.
Patient preference for treatment decision- making, 
decisional conflict, patient expectations, preference for 
quantity of life versus QoL, and retrospective views on 
their decision to receive chemotherapy will be presented 
descriptively with mean (SD) or median (IQR) at each 
timepoint as appropriate.
Sample size
For the primary endpoint, the difference from baseline to 
four cycles will be tested. A mean difference of 10 points 
in EORTC- QLQ- C30 global HRQoL score is deemed to be 
clinically relevant with an effect size of 0.3, where the SD 
of the mean difference is 33.3.38 With a 90% power and a 
two- sided 5% significance level, a total of 119 patients are 
required.38To allow for drop outs, an additional 10% of 
patients will be recruited, giving a total sample size of 132.
We estimate that there will be approximately 30 patients 
in the third- line chemotherapy cohort within the time-
frame of the study.
Missing data
Subjects who have completed online questionnaires will 
not have any missing data unless they have not completed 
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the entire questionnaire. The electronic questionnaires 
have been programmed so that participants are not able 
to proceed to the next question until all of the questions 
on the current page have been answered. If patients have 
not completed the questionnaire, they will be sent an 
electronic reminder to finish the questionnaire within the 
time period specified. Regarding paper questionnaires, 
we will quantify the extent of missing items (ie, number 
of unanswered questions per patient) and describe these 
results in our findings. For the EORTC- QLQ- C30, we 
will follow the EORTC scoring manual guidelines for 
missing data and use imputation where appropriate.58 
For all other questionnaires, scores cannot be calculated 
unless the patient has answered all of the items. We will 
categorise these responses as missing/not answered in 
the presentation of the results so that ‘non- responses’ 
are included in the analysis in order to minimise bias in 
interpretation.
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